Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany. The IM Cannabis news feed on Stock Titan aggregates company-issued press releases and other coverage related to its operations, strategy, governance, and capital markets activity.
Readers can expect frequent corporate updates, such as board and management changes, including appointments and departures of directors and executive officers. These announcements often detail the backgrounds of new appointees and outline how governance changes fit within the company’s broader strategic review.
The news stream also features financial reporting items, including notices about upcoming earnings releases and press releases summarizing interim financial results. These communications may discuss revenue trends, gross margin, non-IFRS measures such as Adjusted EBITDA, and commentary on factors affecting performance in Israel and Germany.
Another key category of coverage involves strategic and transactional developments. IM Cannabis has reported on initiatives to identify additional business opportunities, the signing of a non-binding term sheet to acquire a majority stake in a quantum computing bio data company, and its evaluation of potential expansion into the United States cannabis market, as well as possible divestitures of its German and Israeli operations. Capital markets updates, such as warrant amendments, resale registration statements, and Nasdaq listing compliance notices, are also part of the company’s news flow.
For investors and observers tracking IMCC, this page offers a centralized view of how the company communicates its progress in medical cannabis markets, its strategic review, and its responses to regulatory and market conditions. Users who follow IM Cannabis can use this news feed to monitor developments over time and review the company’s own descriptions of its plans and performance.
IM Cannabis Corp. (NASDAQ: IMCC) announced that its Roma strain was voted Israel's Favourite Strain of the Month for August 2022, highlighting its market momentum following recent restructuring initiatives. The Roma strain, known for its therapeutic benefits, sold 100 kilograms in Israel in August. IMC's efforts include expanding product offerings and streamlining operations, establishing itself as a leader in the Israeli medical cannabis market with over 25 new SKUs launched in the past year. CEO Oren Shuster emphasized the success of these initiatives in enhancing product quality and patient satisfaction.
Avant Brands and IM Cannabis Corp. announced on October 12, 2022, a Licensing Agreement permitting IMC exclusive rights to launch the BLKMKT brand in Israel's medical cannabis market. This agreement enhances their collaboration, allowing IMC to utilize Avant’s premium cannabis products in its offerings. The partnership aims to meet the increasing demand for high-quality cannabis in Israel and strengthens IMC’s leadership in the ultra-premium segment. Avant will provide cannabis grown in Canada, ensuring compliance with regulatory standards.
Avant Brands (OTCQX: AVTBF) and IM Cannabis Corp. (NASDAQ: IMCC) have signed an international trademark licensing agreement allowing IMC exclusive rights to launch the BLKMKT brand in Israel's medical cannabis market. This agreement underlines the robust partnership between the two companies, enhancing IMC's premium product portfolio with Avant's high-quality strains. As part of their evolving collaboration, IMC aims to solidify its standing in the ultra-premium cannabis segment in Israel, catering to a growing demand for top-tier indoor cannabis products.
IM Cannabis Corp. (NASDAQ: IMCC) has completed the second tranche of a non-brokered private placement, issuing 1,112,504 common shares at USD$0.50 each, raising a total of USD$556,252. This brings the total raised from the offering to approximately USD$3 million. The proceeds will be used for general working capital purposes. The transaction involved insider participation from Executive Chairman Marc Lustig, exempting the company from certain minority approval requirements due to the market capitalization less than 25%. All shares are subject to a four-month hold period.
SNDL has successfully completed its first international export of approximately 167 kilograms of premium dried cannabis flower from Canada to Israel in partnership with IM Cannabis Corp. This export is part of a larger agreement to export a total of 1,000 kilograms for distribution in the Israeli medical cannabis market. SNDL aims to expand its international presence and increase revenue from cannabis operations. The collaboration with IMC is expected to enhance the supply chain and product quality in the emerging global cannabis markets.
IM Cannabis Corp. (NASDAQ: IMCC) announced the appointment of Einat Zakariya and Moti Marcus to its board of directors, replacing Vivian Bercovici and Haleli Barath. Zakariya, a CEO in real estate with experience on multiple boards, and Marcus, a CEO in metals with a strong financial background, bring substantial expertise. CEO Oren Shuster highlighted their leadership as pivotal for IMC's growth. The company continues to strengthen its position in the cannabis market across Israel, Canada, and Germany.
On September 8, 2022, Rafael Gabay, a notable shareholder of IM Cannabis Corp. (IMCC), announced his acquisition of 613,496 Common Shares through a non-brokered private placement of 4,887,496 shares at USD$0.50 each, totaling USD$2,443,748. Following this transaction, Mr. Gabay's ownership increased to 8,704,216 shares, representing approximately 11.67% of IMCC's total shares. This marks a slight rise from his previous ownership of 11.61%. The acquisition is intended for general investment purposes and may lead to future transactions, subject to market conditions.
IM Cannabis Corp. (CSE: IMCC, NASDAQ: IMCC) reported a strong Q2 2022, with revenues soaring by 114% year-over-year to $23.8 million. Gross profit rose to $5.6 million, aided by significant operational streamlining, including closures and restructuring, expected to save $6.5 million annually. The company aims for profitability through increased revenue and cost efficiencies while expanding its presence in Germany and Europe. However, net losses widened to $18.98 million, influenced by restructuring costs and increased administrative expenses.
Xinteza API Ltd., a biosynthesis technology company, announced a major expansion of its intellectual property portfolio with a breakthrough in cannabinoid synthesis. This discovery involves a novel, non-cannabis plant-derived production system that enables efficient cannabinoid biosynthesis throughout the entire plant. The system aims to address existing enzymatic and genetic modification challenges in cannabinoid production, enhancing yield, consistency, and cost-effectiveness. CEO Alon Gal emphasized that this innovative approach positions Xinteza at the forefront of cannabinoid sourcing.
IM Cannabis Corp (CSE: IMCC, NASDAQ: IMCC) will release its operational and financial results for Q2 2022 on August 15, 2022, before market opens. The company, based in Israel, Canada, and Germany, focuses on medical and recreational cannabis. A Zoom conference is scheduled for the same day at 9:00 AM ET to discuss these results, followed by a Q&A session for investors. For those unable to attend, a recording will be accessible on the company's website within 24 hours post-call.